Terms: = Pancreatic cancer AND QKI, Hqk, 9444, ENSG00000112531, Q96PU8, QK3, DKFZp586I0923, QK
4 results:
1. An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer.
Ruta V; Naro C; Pieraccioli M; Leccese A; Archibugi L; Cesari E; Panzeri V; Allgöwer C; Arcidiacono PG; Falconi M; Carbone C; Tortora G; Borrelli F; Attili F; Spada C; Quero G; Alfieri S; Doglioni C; Kleger A; Capurso G; Sette C
Cell Rep Med; 2024 Feb; 5(2):101411. PubMed ID: 38325381
[TBL] [Abstract] [Full Text] [Related]
2. hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma.
Xu L; Ma X; Zhang X; Zhang C; Zhang Y; Gong S; Wu N; Zhang P; Feng X; Guo J; Zhao M; Ren Z; Zhang P
Mol Cancer; 2023 Dec; 22(1):195. PubMed ID: 38044421
[TBL] [Abstract] [Full Text] [Related]
3. Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of pancreatic Ductal Adenocarcinoma.
Kong Y; Luo Y; Zheng S; Yang J; Zhang D; Zhao Y; Zheng H; An M; Lin Y; Ai L; Diao X; Lin Q; Chen C; Chen R
Cancer Res; 2023 Sep; 83(18):3077-3094. PubMed ID: 37363990
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of miR-429 as a novel serum biomarker for pancreatic ductal adenocarcinoma and analysis its tumor suppressor function and target genes.
Huang WT; Lin TS; Wu JY; Hong JM; Chen YL; Qiu FN
Eur Rev Med Pharmacol Sci; 2022 Jul; 26(13):4638-4653. PubMed ID: 35856354
[TBL] [Abstract] [Full Text] [Related]
